Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Liu, I Jung ^a   Tsai, Wan Ting ^b   Hsieh, Li En ^b   Chueh, Ling Ling ^b  

^a CARDINAL TIEN COLLEGE OF HEALTHCARE AND MANAGEMENT   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; PEPTIDE; PHENYLALANYLASPARAGINYLALANYLTHREONYLLEUCYLASPARGINYLLEUCYLTHREONYLGLYCYLGLUTAMYLISOLEUCYLASPARTYLASPARTYLLEUCYLGLUTAMYLPHENYLALANYLARGINYLSERYLGLUTAMYLLYSYLLEUCINE; PHENYLALANYLASPARAGINYLALANYLTHREONYLLEUCYLASPARGINYLLEUCYLTHREONYLGLYCYLGLUTAMYLISOLEUCYLASPARTYLASPARTYLLEUCYLGLUTAMYLPHENYLALANYLARGINYLSERYLGLUTAMYLLYSYLLEUCYLHISTIDYLASPARAGINYLTHREONYLTHREONYLVALYLGLUTAMYLLEUCINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS; CORONAVIRUS INFECTION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENTIATION; DRUG SYNTHESIS; FETUS; NONHUMAN; VIRUS INHIBITION; VIRUS PLAQUE; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CATS; CELL LINE; CORONAVIRUS INFECTIONS; CORONAVIRUS, FELINE; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HUMANS; INTERFERON-ALPHA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS REPLICATION;

EID: 84891807614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082081     Document Type: Article

References (43)

1. Carstens EB (2010) Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2009). Arch Virol 155: 133-146. doi:10.1007/s00705-009-0547-x. PubMed: 19960211.
2. Fehr D, Holznagel E, Bolla S, Hauser B, Herrewegh AA et al. (1997) Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions. Vaccine 15: 1101-1109. doi:10.1016/S0264-410X(97)00006-6. PubMed: 9269053.
3. Pedersen NC (2009) A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg 11: 225-258. doi:10.1016/j.jfms.2008.09. 008. PubMed: 19254859.
4. Hartmann K, Ritz S (2008) Treatment of cats with feline infectious peritonitis. Vet Immunol Immunopathol 123: 172-175. doi:10.1016/j.vetimm.2008. 01.026. PubMed: 18395801.
5. Haagmans BL, Osterhaus AD (2006) Coronaviruses and their therapy. Antiviral Res 71: 397-403. doi:10.1016/j.antiviral.2006.05.019. PubMed: 16837072.
6. Hsieh LE, Lin CN, Su BL, Jan TR, Chen CM et al. (2010) Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral Res 88: 25-30. doi:10.1016/j.antiviral.2010.06.010. PubMed: 20603153.
7. Weiss RC, Toivio-Kinnucan M (1988) Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta). Interferon - Am J Vet Res 49: 1329-1335.
8. McDonagh P, Sheehy PA, Norris JM (2011) In vitro inhibition of feline coronavirus replication by small interfering RNAs. Vet Microbiol 150: 220-229. doi:10.1016/j.vetmic.2011.01.023. PubMed: 21367541.
9. Regan AD, Shraybman R, Cohen RD, Whittaker GR (2008) Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet Microbiol 132: 235-248. doi:10.1016/j.vetmic.2008.05.019. PubMed: 18606506.
10. van der Meer FJ, de Haan CA, Schuurman NM, Haijema BJ, Verheije MH et al. (2007) The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J Antimicrob Chemother 60: 741-749. doi:10.1093/jac/dkm301. PubMed: 17704516.
11. Balzarini J, Keyaerts E, Vijgen L, Vandermeer F, Stevens M et al. (2006) Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. J Antimicrob Chemother 57: 472-481. doi:10.1093/jac/dki481. PubMed: 16387746.
12. Ballesteros ML, Sánchez CM, Enjuanes L (1997) Two amino acid changes at the N-terminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism. Virology 227: 378-388. doi:10.1006/viro.1996.8344. PubMed: 9018137.
13. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810. doi:10.1146/annurev.biochem.70.1.777. PubMed: 11395423.
14. Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ et al. (1999) Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol 16: 3-9. doi:10.1080/096876899294706. PubMed: 10332732.
15. Kielian M, Rey FA (2006) Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 4: 67-76. doi:10.1038/nrmicro1326. PubMed: 16357862.
16. Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS et al. (2009) Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. Antiviral Res 81: 82-87. doi:10.1016/j.antiviral.2008.10.001. PubMed: 18983873.
17. Liu SW, Xiao GF, Chen YB, He YX, Niu JK et al. (2004) Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363: 938-947. doi:10.1016/S0140-6736(04)15788-7. PubMed: 15043961.
18. Yuan K, Yi L, Chen J, Qu X, Qing T et al. (2004) Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun 319: 746-752. doi:10.1016/j.bbrc.2004.05.046. PubMed: 15184046.
19. Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ et al. (2004) Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A 101: 8455-8460. doi:10.1073/pnas.0400576101. PubMed: 15150417.
20. Henkel J (1999) Attacking AIDS with a 'cocktail' therapy? FDA Consum 33: 12-17. PubMed: 10443176.
21. Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333: 450-451. doi:10.1056/NEJM199508173330710. PubMed: 7616996.
22. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492. doi:10.1056/NEJM199811193392101. PubMed: 9819446.
23. Pedersen NC, Boyle JF, Floyd K (1981) Infection studies in kittens, using feline infectious peritonitis virus propagated in cell culture. Am J Vet Res 42: 363-367. PubMed: 6267959.
24. Vogel L, Van der Lubben M, te Lintelo EG, Bekker CP, Geerts T et al. (2010) Pathogenic characteristics of persistent feline enteric coronavirus infection in cats. Vet Res 41: 71. doi:10.1051/vetres/2010043. PubMed: 20663472.
25. Lin CN, Su BL, Wu CW, Hsieh LN, Chueh LL (2009) Isolation and identification of a novel feline coronavirus from a kitten with naturally occurring feline infectious peritonitis in Taiwan. Taiwan Vet J 35: 145.
26. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77: 8801-8811. doi:10.1128/JVI.77.16.8801-8811.2003. PubMed: 12885899.
27. Porotto M, Yokoyama CC, Palermo LM, Mungall B, Aljofan M et al. (2010) Viral entry inhibitors targeted to the membrane site of action. J Virol 84: 6760-6768. doi:10.1128/JVI.00135-10. PubMed: 20357085.
28. Medinas RJ, Lambert DM, Tompkins WA (2002) C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. J Virol 76: 9079-9086. doi:10.1128/JVI.76.18.9079-9086.2002. PubMed: 12186891.
29. Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X et al. (2011) Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem 286: 15854-15861. doi:10.1074/jbc.M110.207084. PubMed: 21454542.
30. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R et al. (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 93: 2186-2191. doi:10.1073/pnas.93.5.2186. PubMed: 8700906.
31. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91: 9770-9774. doi:10.1073/pnas.91.21.9770. PubMed: 7937889.
32. Root MJ, Kay MS, Kim PS (2001) Protein design of an HIV-1 entry inhibitor. Science 291: 884-888. doi:10.1126/science.1057453. PubMed: 11229405.
33. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4: 1302-1307. doi:10.1038/3293. PubMed: 9809555.
34. Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365: 113. doi:10.1038/365113a0. PubMed: 8371754.
35. He Y, Xiao Y, Song H, Liang Q, Ju D et al. (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283: 11126-11134. doi:10.1074/jbc.M800200200. PubMed: 18303020.
36. Pan C, Lu H, Qi Z, Jiang S (2009) Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS 23: 639-641. doi:10.1097/QAD.0b013e328325a4cd. PubMed: 19242316.
37. Pang W, Tam SC, Zheng YT (2009) Current peptide HIV type-1 fusion inhibitors. Antivir Chem Chemother 20: 1-18. doi:10.3851/IMP1369. PubMed: 19794228.
38. Xu Y, Liu Y, Lou Z, Qin L, Li X et al. (2004) Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem 279: 30514-30522. doi:10.1074/jbc. M403760200. PubMed: 15123674.
39. Watanabe S, Takada A, Watanabe T, Ito H, Kida H et al. (2000) Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 74: 10194-10201. doi:10.1128/JVI.74.21.10194-10201.2000. PubMed: 11024148.
40. Weiss RC, Oostrom-Ram T (1989) Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet Microbiol 20: 255-265. doi:10.1016/0378-1135(89)90049- 7. PubMed: 2549687.
41. Weiss RC, Cox NR, Boudreaux MK (1993) Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther 16: 301-316. doi:10.1111/j.1365-2885.1993.tb00177.x. PubMed: 8230401.
42. Ball RA, Kinchelow T, Group ISRS (2003) Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J; Am Acad Dermatol 49: 826-831.
43. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, et al. (2002) The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 18: 685-693.